Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior
systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three
week cycles until unacceptable toxicity, death, progressive disease or withdrawal.